A just discovered exploratory Phase...

A just discovered exploratory Phase 2 study of Betaferon/Betaseron (Schering AG, Berlin, Germany, interferon beta 1b) in subdues with primary progressive multiple sclerosis (MS) showed that the studious mood drug was statistically more efficacious than placebo in reducing M lesions as measured by means of MRI. In the double-blind, single-center consideration 73 subjects with EDS scores of 30 to 70 were randomized to receive either 8 MIU (250 [micro]g) of the close attention drug or placebo every other day for couple years. Of all